Bitfarms just posted its latest earnings report for Q3 2025, and the results were straight-up disappointing. The company reported $69.25 million in revenue for the quarter ending September, falling about 16.7% short of what analysts at Zacks were expecting. That’s a big miss for a company that’s been riding high this year in terms of […]Bitfarms just posted its latest earnings report for Q3 2025, and the results were straight-up disappointing. The company reported $69.25 million in revenue for the quarter ending September, falling about 16.7% short of what analysts at Zacks were expecting. That’s a big miss for a company that’s been riding high this year in terms of […]

Bitfarms revenue misses estimates by 16.7% as Q3 results disappoint investors

Bitfarms just posted its latest earnings report for Q3 2025, and the results were straight-up disappointing. The company reported $69.25 million in revenue for the quarter ending September, falling about 16.7% short of what analysts at Zacks were expecting.

That’s a big miss for a company that’s been riding high this year in terms of share price. On the profit side, Bitfarms logged a net loss of $0.02 per share, which exactly matched the Zacks estimate, but still shows there’s trouble under the hood.

Compared to last year’s Q3 loss of $0.09 per share, the company has narrowed the gap, but that doesn’t change the fact that earnings surprises have been rare. In fact, over the past four quarters, Bitfarms has only beaten earnings estimates once.

A quarter ago, analysts thought the company would lose just $0.01 per share, but Bitfarms ended up posting $0.02, doubling the loss and delivering a nasty ‑100% surprise.

Loss narrows, but revenue miss drags outlook

The year-over-year revenue growth, from $44.85 million in Q3 2024 to $69.25 million this quarter, sounds solid, but it doesn’t matter much when Wall Street expected way more. This quarter’s miss brought the company’s revenue beat record down to two out of the last four quarters.

Despite the Q3 letdown, Bitfarms stock is still up 112.8% year-to-date, way ahead of the S&P 500’s 16.5% gain. But that outperformance doesn’t mean much right now. The immediate focus has turned to what Geoff Morphy, the CEO, and his team will say on the earnings call. Investors want answers, what’s driving the continued misses, and what’s the plan to turn it around?

Right before the earnings dropped, the revisions trend for the company was already looking weak. That same trend now feeds into the company’s Zacks Rank #4 (Sell) rating, meaning analysts don’t expect this stock to beat the market any time soon. The future will depend on how much earnings estimates move now that the results are out.

For the next quarter, the current consensus is a loss of $0.01 per share on expected revenues of $86.81 million. For the full fiscal year, analysts are forecasting a loss of $0.15 per share on $314.54 million in total revenue. These estimates will definitely be under review after the latest numbers.

Bitfarms outlook dims as peers prepare results

The industry isn’t dragging Bitfarms down either. The Zacks Technology Services industry, which the company is part of, currently ranks in the top 27% out of more than 250 tracked industries. That means it’s not the sector, it’s the company.

There’s also a spotlight on MindWalk Holdings Corp., a peer in the same industry, which hasn’t reported yet for its October quarter. Analysts expect MindWalk to post a $0.01 per share loss, a major 85.7% improvement from the same period last year.

Revenue for MindWalk is projected at $4 million, down 10.9% year-over-year. Notably, MindWalk’s EPS estimates haven’t moved in 30 days, a sign of stability investors may find attractive if Bitfarms can’t get it together.

Ben Gagnon, the CEO of Bitfarms, said on Thursday during the call event that even though the Washington property makes up less than 1% of the company’s total buildable portfolio, switching it to a GPU-as-a-Service site could bring in more net operating income than anything they’ve ever made from Bitcoin mining.

Miners like Cipher and Terawulf, who’ve already stepped into AI infrastructure, have pulled in heavyweight backers like SoftBank and Google to co-develop data centers. These deals are tied to multi-billion-dollar revenue projections, and they’re also helping these companies stack up more funds through debt.

What happens next for Bitfarms will come down to whether Wall Street decides to give it another shot or pulls the plug. Right now, the company’s mixed record on earnings, weak revisions trend, and underwhelming Q3 numbers make that a tough call.

Get seen where it counts. Advertise in Cryptopolitan Research and reach crypto’s sharpest investors and builders.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23